J Parkinsons Dis 2020 Jan 28
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Padmanabhan S, Lanz TA, Gorman D, Wolfe M, Joyce A, Cabrera C, Lawrence-Henderson R, Levers N, Joshi N, Ma T, Liong C, Narayan S, Alcalay RN, Hutten SJ, Baptista MAS, Merchant K
The phosphorylated form of LRRK2, pS935 LRRK2, has been proposed as a target modulation biomarker for LRRK2 inhibitors. The primary aim of the study w ...
Read More
Source: PubMed
Nat Commun
Human and mouse essentiality screens as a resource for disease gene discovery.
Cacheiro P, Muñoz-Fuentes V, Murray SA, Dickinson ME, Bucan M, Nutter LMJ, Peterson KA, Haselimashhadi H, Flenniken AM, Morgan H, Westerberg H, Konopka T, Hsu CW, Christiansen A, Lanza DG, Beaudet AL, Heaney JD, Fuchs H, Gailus-Durner V, Sorg T, Prochazka J, Novosadova V, Lelliott CJ, Wardle-Jones H, Wells S, Teboul L, Cater H, Stewart M, Hough T, Wurst W, Sedlacek R, Adams DJ, Seavitt JR, Tocchini-Valentini G, Mammano F, Braun RE, McKerlie C, Herault Y, de Angelis MH, Mallon AM, Lloyd KCK, Brown SDM, Parkinson H, Meehan TF, Smedley D
The identification of causal variants in sequencing studies remains a considerable challenge that can be partially addressed by new gene-specific know ...
Read More
Source: PubMed
J. Biol. Chem. 2020 Jan 31
Amyloid aggregates of the deubiquitinase OTUB1 are neurotoxic, suggesting that they contribute to the development of Parkinson's disease.
Kumari R, Kumar R, Kumar S, Singh AK, Hanpude P, Jangir D, Maiti TK
Parkinson's disease (PD) is a multifactorial malady and the second most common neurodegenerative disorder, characterized by loss of dopaminergic neuro ...
Read More
Source: PubMed
J Integr Med 2020 Jan 16
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Shinjyo N, Parkinson J, Bell J, Katsuno T, Bligh A
A growing number of epidemiological studies indicate that metabolic syndrome (MetS) and its associated features play a key role in the development of ...
Read More
Source: PubMed
BMC Neurol
Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.
van Poppelen D, Sisodia V, de Haan RJ, Dijkgraaf MGW, Schuurman PR, Geurtsen GJ, Berk AEM, de Bie RMA, Dijk JM
Both Deep Brain Stimulation (DBS) and Continuous intrajejunal Levodopa Infusion (CLI) are effective therapies for the treatment of Parkinson's disease ...
Read More
Source: PubMed
